858-449-1310 contact@somatek.com

As widely reported, earlier this week FDA approved the first in a novel class of immuno-oncology drugs called bispecific T-cell engagers for the treatment of small cell carcinoma. Small cell carcinoma, an aggressive type of lung cancer, currently has a few effective treatments and a dismal prognosis. Bispecific T-cell engagers are antibody-based proteins that combine the antigen binding domains of two different antibodies, one recognizing a cell surface molecule on cancer cells, the other one binding to a protein on the surface of T cells.  T cell engagers bring cancer cells and T cells in close proximity and activate the T cell to kill the cancer cell. Amgen has developed a T cell engager that reacts with delta-like ligand 3 (DLL3) a protein highly expressed in SCLC and the CD3 molecule on T cells. Read the Amgen press release on the accelerated approval of IMDELLTRA (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.